Antiviral Setback: Valacyclovir Linked to Faster Cognitive Decline in Alzheimer’s Patients

NEW YORK — A long-debated theory that treating common viral infections could slow the progression of Alzheimer’s disease has faced a significant setback. A multi-center clinical trial led by investigators at the New York State Psychiatric Institute and Columbia University Medical Center has found that the antiviral drug valacyclovir did not help patients with early symptomatic Alzheimer’s. Instead, the study revealed a troubling outcome: patients taking the medication experienced significantly faster cognitive decline compared to those receiving a placebo.

The findings, published recently in JAMA, challenge the “pathogen hypothesis” of Alzheimer’s—the idea that dormant viruses like herpes simplex virus type 1 (HSV-1) might trigger the brain inflammation and plaque buildup characteristic of the disease.

The Viral Connection: Why Researchers Looked at Herpes

For years, scientists have observed a curious link between HSV-1—the virus typically responsible for cold sores—and the pathology of Alzheimer’s disease. HSV-1 is known to stay dormant in the body after an initial infection, but it can travel to the brain and settle in areas critical for memory, such as the temporal lobe.

Previous research provided a compelling case for testing antivirals:

• Autopsy Evidence: Studies have found HSV-1 DNA in 90% of amyloid plaques, the toxic protein clusters found in Alzheimer’s brains.

• Cell Culture Success: In laboratory settings, antiviral drugs like acyclovir reduced the accumulation of beta-amyloid and “tau” tangles (another hallmark of the disease).

• Animal Models: Infections in mice have been shown to trigger an increase in the very proteins that lead to neurodegeneration.

Given these signals, valacyclovir—a safe, widely used drug for herpes—seemed like a promising candidate to “halt” the viral contribution to brain rot.

The Study: A Controlled Test of the Theory

The trial, titled “Valacyclovir Treatment of Early Symptomatic Alzheimer Disease,” enrolled 120 participants who met two specific criteria:

1. A diagnosis of mild cognitive impairment or early-stage Alzheimer’s disease.

2. Positive blood tests for HSV-1 or HSV-2 antibodies, indicating they carried the virus.

Participants were split into two groups of 60. One group received 4 grams of valacyclovir daily, while the other received an identical-looking placebo. To ensure the highest level of scientific rigor, the study was “double-blind,” meaning neither the patients nor the doctors knew who was receiving the active drug until the trial ended at 78 weeks.

Surprising Results: “Worse Than Nothing”

Researchers used the Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) to measure memory, language, and orientation. On this scale, a higher score indicates greater impairment.

While both groups saw their scores rise over the 18-month period—which is expected in a progressive disease—the gap between them was stark. The valacyclovir group’s scores rose by 10.86 points, while the placebo group’s scores rose by only 6.92 points. Essentially, those on the antiviral medication lost cognitive function roughly 50% faster than those who took nothing at all.

“The results were not what we hoped for,” noted the research team. Despite the drug being successfully absorbed into the bloodstream and cerebrospinal fluid, it failed to reduce the buildup of amyloid or tau proteins in the brain.

Expert Perspectives and Public Health Implications

The medical community is now grappling with why a drug intended to help may have caused harm.

“This is a sobering reminder that what works in a petri dish or a mouse model does not always translate to the human brain,” says Dr. Elena Rossi, a neurologist not involved in the study. “While the ‘virus theory’ of Alzheimer’s isn’t necessarily dead, this specific pathway—using valacyclovir at this stage of the disease—appears to be a dead end.”

Experts are uncertain why the decline was faster in the treatment group. Some hypothesize that the drug might have interfered with protective mechanisms in the brain, or that the high dosage required for the trial (4 grams daily) may have had subtle neurotoxic effects in an already vulnerable population.

What This Means for Patients

For families and caregivers, the takeaway is clear: Valacyclovir should not be used as a treatment for Alzheimer’s disease.

While the drug remains safe and effective for its intended use—treating shingles, cold sores, and genital herpes—this study suggests it has no “off-label” benefit for dementia. In fact, for those with early-stage Alzheimer’s, it may be detrimental.

“We must follow the data,” says Dr. Robert Egan, who reviewed the findings. “Patients and providers should stick to FDA-approved Alzheimer’s treatments and avoid experimental use of antivirals for cognitive health outside of a strictly monitored clinical trial.”

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

Primary Study:

• Devanand, D. P., et al. (2025). Valacyclovir Treatment of Early Symptomatic Alzheimer Disease. JAMA. DOI: 10.1001/jama.2025.21738.